Glaxo to launch five vaccines over five years

Share this article:
GlaxoSmithKline said it expects to launch five major vaccines in the next five years with the potential to reach total annual sales between $10 billion and $18 billion.
Among the vaccines is Cervarix, a cervical-cancer vaccine, considered to be the most promising product of the group.
Filing for Cervarix approval in Europe is expected in early 2006 with a U.S. filing expected later next year. Glaxo said Cervarix could achieve sales between $3.5 billion and $7 billion.
Other vaccines being readied for launch by 2010 include Rotarix for gastroenteritis, Streptorix for pneumococcal infections, a combination vaccine for meningitis and an improved vaccine for influenza.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.